难治性功能性胃肠病发病机制进展及其对药物治疗学的启示  

Key Points of Drug Therapy for Refractory Functional Gastrointestinal Disorders Based on Advances in Pathogenesis

作　　者：季洁如[1] 陈胜良[2] JI Jieru;CHEN Shengliang(Department of Gastroenterology,Shanghai Pudong New Area People＇s Hospital,Shanghai（201200;Division of Gastroenterology and Hepatology,Renji Hospital,School of Medicine,Shanghai Jiao Tong University;Shanghai Institute of Digestive Disease,Shangha)

机构地区：[1]上海市浦东新区人民医院消化内科,201200 [2]上海交通大学医学院附属仁济医院消化内科、上海市消化疾病研究所

出　　处：《胃肠病学》2018年第9期513-517,共5页Chinese Journal of Gastroenterology

摘　　要：功能性胃肠病(FGIDs)是以症状为处置目标的一类疾病。FGIDs病因和发病机制复杂,又极具个体化特点,故很难把握治疗靶点,精准选择治疗药物是难治性FGIDs的临床挑战之一。近年来,关于FGIDs症状产生机制和发病机制的研究有不少进展,本文运用心身消化整体医学思维,分析这些进展机制中的关键可干预靶点,探讨提升难治性FGIDs的若干实用药物治疗策略。Functional gastrointestinal disorders （FGIDs） is a kind of disease with symptonls being the main target of treatment. The etiology- and pathogenesis of FGIDs are complex and extremely individualized, therefore it is difficult to find the therapeutic target and to prescribe precisely. This is the biggest challenge in the clinical practice of refractory FGIDs. Fortunately, progresses are constantly being made on the understanding of meehanisnls of FGIDs symptonls. This article presented the new thinking in strategy for management of refractory FGIDs with a psychosomatic holistie view on gastroenterology, analyzing the key interventional targets in its developmental mechanisms and discussing several practical drug treatment strategy.

关 键 词：难治性功能性胃肠病 心身消化病学 肠-脑互动 肠道微生态 十二指肠-Oddi括约肌功能紊乱 胆汁酸 

分 类 号：R57[医药卫生—消化系统]